{"id":"rifampicin-alone","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"common","effect":"Orange/red discoloration of body fluids"},{"rate":"1-5","effect":"Rash"},{"rate":"1-3","effect":"Gastrointestinal disturbance"},{"rate":"<1","effect":"Thrombocytopenia"},{"rate":"common","effect":"Drug interactions (enzyme induction)"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampicin binds to the bacterial RNA polymerase β-subunit and inhibits RNA synthesis by blocking the path of the elongating RNA transcript. This mechanism is highly selective for bacterial RNA polymerase and has minimal effect on eukaryotic RNA polymerases, making it effective as an antibiotic. It is bactericidal and works against a broad spectrum of gram-positive and gram-negative bacteria.","oneSentence":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:58.910Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (drug-susceptible)"},{"name":"Leprosy"},{"name":"Atypical mycobacterial infections"},{"name":"Prophylaxis of meningococcal meningitis"},{"name":"Brucellosis"}]},"trialDetails":[{"nctId":"NCT04930744","phase":"PHASE2","title":"Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-08-26","conditions":"Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection","enrollment":112},{"nctId":"NCT05586230","phase":"PHASE1","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-03","conditions":"Tuberculosis, Rifampicin Resistant Tuberculosis","enrollment":72},{"nctId":"NCT07374224","phase":"PHASE1","title":"A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2026-03-05","conditions":"Clinical Pharmacology","enrollment":28},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT07429331","phase":"PHASE1","title":"Drug Interaction and Food Effect Study of CS0159","status":"NOT_YET_RECRUITING","sponsor":"Cascade Pharmaceuticals, Inc","startDate":"2026-03","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT07429760","phase":"NA","title":"Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT00750841","phase":"PHASE1","title":"Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2008-09-09","conditions":"Solid Tumors","enrollment":64},{"nctId":"NCT07420881","phase":"NA","title":"Start4All - Start Taking Action for TB Diagnosis (DARE-TB)","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2026-03-01","conditions":"TB - Tuberculosis","enrollment":60000},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT07069582","phase":"PHASE1","title":"Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-04-01","conditions":"Tuberculosis Infection, Healthy Volunteer, Breastfeeding","enrollment":60},{"nctId":"NCT06318416","phase":"PHASE1","title":"Precision Rifampin Trial for Personalized Dosing","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2025-10-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT07357610","phase":"PHASE1","title":"An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2026-01-05","conditions":"Healthy Adult Participants","enrollment":60},{"nctId":"NCT06489431","phase":"PHASE3","title":"Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2023-12-04","conditions":"Erectile Dysfunction, Penile Prosthesis; Complications, Infection or Inflammation","enrollment":200},{"nctId":"NCT07134478","phase":"PHASE1","title":"Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-10-28","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT07313215","phase":"NA","title":"Rifampin-combined Antibiotic Therapy for Staphylococcal PJI","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-11-13","conditions":"Periprosthetic Joint Infection","enrollment":428},{"nctId":"NCT04630145","phase":"PHASE2, PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","enrollment":129},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT05822544","phase":"PHASE1","title":"Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes","status":"RECRUITING","sponsor":"OrsoBio, Inc","startDate":"2023-04-22","conditions":"Healthy Subjects, Obesity, Type 2 Diabetes","enrollment":564},{"nctId":"NCT05592223","phase":"PHASE1","title":"Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-06","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT06024915","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-09-21","conditions":"Myelofibrosis","enrollment":40},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05069688","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-07","conditions":"Pediatric HIV Infection, Tuberculosis Infection","enrollment":20},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT07196449","phase":"PHASE1","title":"Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2025-05-14","conditions":"Drug Drug Interaction (DDI)","enrollment":12},{"nctId":"NCT05526885","phase":"NA","title":"Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa","status":"COMPLETED","sponsor":"Klaus Reither","startDate":"2022-09-07","conditions":"Tuberculosis","enrollment":20000},{"nctId":"NCT05338489","phase":"PHASE1","title":"A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-05-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT06064539","phase":"PHASE1","title":"Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-18","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT06222372","phase":"NA","title":"Novel Interventions and Diagnostic Tests for Leprosy","status":"RECRUITING","sponsor":"Annemieke Geluk","startDate":"2020-03-04","conditions":"Leprosy","enrollment":1100},{"nctId":"NCT07014488","phase":"PHASE1","title":"A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-06-20","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT02906007","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-09-21","conditions":"Tuberculosis, HIV","enrollment":54},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":"Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis","enrollment":120},{"nctId":"NCT04311502","phase":"PHASE2","title":"Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-05","conditions":"HIV, Tuberculosis","enrollment":104},{"nctId":"NCT05473195","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2022-12-06","conditions":"Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)","enrollment":105},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT07056842","phase":"PHASE1","title":"This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2025-07-20","conditions":"Obesity &Amp; Overweight","enrollment":32},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT07058090","phase":"PHASE1","title":"Comparison of the Outcome of Treatment With Silymarin or N-Aceylcysteine in Patients Taking Anti-Tuberculous Drugs for Tuberculosis at a Tertiary Care Hospital , Karachi","status":"NOT_YET_RECRUITING","sponsor":"Liaquat National Hospital & Medical College","startDate":"2025-07","conditions":"Drug Induced Liver Injury, Tuberculosis (TB)","enrollment":410},{"nctId":"NCT03814200","phase":"PHASE1","title":"A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2019-01-03","conditions":"Healthy Subject","enrollment":14},{"nctId":"NCT05175794","phase":"","title":"Triage Test for All Oral DR-TB Regimen (TRiAD Study)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-05-26","conditions":"Drug Resistant Tuberculosis, MDR-TB, XDR-TB","enrollment":786},{"nctId":"NCT05057949","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-11-24","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT06835465","phase":"PHASE1","title":"A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2025-02-21","conditions":"Healthy Participants","enrollment":18},{"nctId":"NCT02846519","phase":"PHASE1","title":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-02-26","conditions":"Healthy","enrollment":66},{"nctId":"NCT06162169","phase":"PHASE1","title":"A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-11-25","conditions":"Healthy Subjects","enrollment":66},{"nctId":"NCT06771050","phase":"PHASE4","title":"Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform (ROADMAP) Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Newcastle, Australia","startDate":"2025-03-26","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Large Joint Prosthetic Joint Infections","enrollment":2500},{"nctId":"NCT03662022","phase":"PHASE3","title":"Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2019-01-02","conditions":"Leprosy","enrollment":144000},{"nctId":"NCT04537715","phase":"PHASE1","title":"Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels","status":"COMPLETED","sponsor":"Epizyme, Inc.","startDate":"2020-04-23","conditions":"All Malignancies, Advanced Malignancies, Hematologic Malignancy","enrollment":42},{"nctId":"NCT06822166","phase":"PHASE1","title":"Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride","status":"COMPLETED","sponsor":"Ahon Pharmaceutical Co., Ltd.","startDate":"2023-12-04","conditions":"Interaction Drug Food","enrollment":68},{"nctId":"NCT06701136","phase":"PHASE1","title":"Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","startDate":"2025-05-12","conditions":"Rifampicin-Resistant Pulmonary Tuberculosis Patients","enrollment":16},{"nctId":"NCT06811792","phase":"","title":"Intrathecal Therapy for Adult Tuberculous Meningitis: Impact on Clinical Outcomes","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2010-01-01","conditions":"Tuberculous Meningitis","enrollment":837},{"nctId":"NCT02661893","phase":"PHASE1","title":"A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-01","conditions":"Healthy","enrollment":14},{"nctId":"NCT02770222","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-06","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT02729467","phase":"PHASE1","title":"A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-03","conditions":"Healthy","enrollment":33},{"nctId":"NCT05134337","phase":"PHASE1","title":"Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2020-02-12","conditions":"Healthy Volunteers","enrollment":27},{"nctId":"NCT06255951","phase":"PHASE1","title":"Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2024-03-12","conditions":"NSCLC","enrollment":48},{"nctId":"NCT06619951","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2024-09-18","conditions":"Locally Advanced or Metastatic Solid Tumor","enrollment":56},{"nctId":"NCT05899829","phase":"PHASE1","title":"Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2023-06-21","conditions":"Cough, Healthy","enrollment":42},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT03800381","phase":"","title":"Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":92},{"nctId":"NCT05357820","phase":"PHASE1","title":"A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK","status":"COMPLETED","sponsor":"Nuvation Bio Inc.","startDate":"2021-07-19","conditions":"Solid Tumor","enrollment":56},{"nctId":"NCT06662773","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study for TQB3616","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11","conditions":"Healthy","enrollment":40},{"nctId":"NCT06658964","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-11-05","conditions":"ADPKD (autosomal Dominant Polycystic Kidney Disease)","enrollment":48},{"nctId":"NCT03994211","phase":"PHASE1","title":"Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-05-29","conditions":"Solid Tumor","enrollment":25},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT03082183","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-03-28","conditions":"Healthy","enrollment":16},{"nctId":"NCT05406479","phase":"PHASE2","title":"Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-07-14","conditions":"Leprosy","enrollment":313},{"nctId":"NCT06562088","phase":"PHASE1","title":"A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-08-16","conditions":"Healthy Adult Subject","enrollment":40},{"nctId":"NCT06089733","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021","status":"COMPLETED","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2023-04-11","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT04121195","phase":"PHASE2, PHASE3","title":"Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2020-10-30","conditions":"HIV/AIDS, Tuberculosis","enrollment":26},{"nctId":"NCT06492525","phase":"PHASE1","title":"A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2024-07","conditions":"Healthy","enrollment":36},{"nctId":"NCT06484530","phase":"PHASE4","title":"Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-03-12","conditions":"Tuberculosis (TB), Isoniazid Toxicity, Rifampicin Toxicity","enrollment":116},{"nctId":"NCT05443178","phase":"PHASE1","title":"Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-01-04","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT05597280","phase":"PHASE3","title":"Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2023-03-22","conditions":"Leprosy","enrollment":124000},{"nctId":"NCT05255276","phase":"PHASE1","title":"PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2022-02-02","conditions":"Healthy Adults","enrollment":36},{"nctId":"NCT05283967","phase":"","title":"Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2019-01-01","conditions":"Tuberculosis","enrollment":150},{"nctId":"NCT02174250","phase":"PHASE1","title":"The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2014-06","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT03782662","phase":"PHASE1","title":"A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":82},{"nctId":"NCT06348290","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-04-01","conditions":"Solid Tumor, Adult","enrollment":72},{"nctId":"NCT06332053","phase":"PHASE1","title":"A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-04-01","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT05635110","phase":"PHASE1","title":"Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-12-15","conditions":"Pain","enrollment":31},{"nctId":"NCT05021731","phase":"PHASE4","title":"Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Miguel Santín","startDate":"2024-04-20","conditions":"Latent Tuberculosis, Kidney Failure","enrollment":225},{"nctId":"NCT05902221","phase":"PHASE3","title":"Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-03-30","conditions":"Infections Joint Prosthetic","enrollment":235},{"nctId":"NCT03151499","phase":"PHASE1","title":"Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-05-30","conditions":"Healthy","enrollment":15},{"nctId":"NCT05602597","phase":"PHASE1","title":"HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-06-01","conditions":"Relapsed or Refractory Lymphoma","enrollment":59},{"nctId":"NCT04088019","phase":"","title":"Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive","status":"UNKNOWN","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2019-10-30","conditions":"Tuberculosis; Uveitis (Manifestation), Anti-Tuberculous Drug Reaction, Tuberculous Uveitis","enrollment":50},{"nctId":"NCT06198556","phase":"PHASE1","title":"Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-14","conditions":"Advanced Solid Tumor","enrollment":18},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT04694586","phase":"PHASE2","title":"Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide","status":"SUSPENDED","sponsor":"University Hospital, Linkoeping","startDate":"2022-11-30","conditions":"Tuberculosis, Pulmonary","enrollment":40},{"nctId":"NCT06165822","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12","conditions":"Advanced Malignant Neoplasm","enrollment":40},{"nctId":"NCT04721795","phase":"PHASE2, PHASE3","title":"Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)","status":"COMPLETED","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2021-01-19","conditions":"Tuberculosis, Pulmonary, Tuberculosis","enrollment":150},{"nctId":"NCT05685719","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558","status":"COMPLETED","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","startDate":"2023-01-04","conditions":"COVID-19 Pneumonia","enrollment":37},{"nctId":"NCT03678688","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-18","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT06108453","phase":"PHASE1","title":"A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Methotrexate in Elderly Subjects","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2023-08-21","conditions":"Drug Interactions","enrollment":10},{"nctId":"NCT06090123","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study for TPN171H","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2020-01-01","conditions":"Erectile Dysfunction","enrollment":24},{"nctId":"NCT03882177","phase":"PHASE2","title":"StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-21","conditions":"Tuberculosis, Pulmonary Tuberculosis","enrollment":16},{"nctId":"NCT02807116","phase":"PHASE1","title":"Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2015-01","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":"Tuberculosis, Meningeal, Linezolid","enrollment":36},{"nctId":"NCT06004947","phase":"PHASE1","title":"A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-01-14","conditions":"Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":32},{"nctId":"NCT05826574","phase":"PHASE1","title":"A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2023-05-10","conditions":"Healthy Volunteers","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rifampicin alone","genericName":"Rifampicin alone","companyName":"Miguel Santín","companyId":"miguel-sant-n","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (drug-susceptible), Leprosy, Atypical mycobacterial infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}